Skip to content
CityAM
Main navigation
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Tech
      • Banking
      • FTSE 100 Live
      • Retail
      • Insurance
      • Legal
      • Property
      • Transport
      • Markets
    • From our partners
      • AON
      • Bayes Business School
      • Canada BIDs
      • Central London Alliance CIC
      • Destination City
      • Halkin
      • Olympia
      • Inside Saudi
      • Tottenham Hotspur Stadium
      • Santander X
      • YEAR SIX Dividend
    • Featured

      Starmer agrees investment deal with Japan as EU deal questioned

      UK and Japan leaders discuss bilateral trade agreements at a high-level government meeting in London.

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
    • From our partners
      • The Morning Briefing: SBS x CityAM
      • Aramco Team Series
      • LIV Golf
    • Featured

      Adidas, Burberry and so much Beckham: The six best 2026 World Cup ad campaigns

      A screenshot capturing a significant moment from a news broadcast on June 11, 2026, at 12:17 PM, highlighting key details.

      Submit a story

      Tell us your story.

      Submit
  • Life&Style
    • Life&Style
      • Life&Style
      • Toast the City Awards
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • Media Speak Hub
    • Featured

      The best places to eat sandwiches in Lisbon, from bifanas to pregos

      Bifana do Afonsos famous bifana sandwich showcasing tender pork in a freshly baked roll with savory sauce.

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • Events
  • Latest Paper
Monday 11 May 2026 7:01 am

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 2026

By: Business Wire

Add as a preferred source on Google

Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/

The MEVION S250-FIT™ Proton Therapy System

Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology.

Stanford Medicine: First S250-FIT Installation

On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a standard 110 m² (1,200 sq ft) LINAC vault inside the existing Stanford Medicine Cancer Center in Palo Alto, without constructing a new building.

“With FIT™, proton therapy is no longer limited by infrastructure,” said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems. “For the first time, it can be deployed within the same clinical and operational framework as conventional radiotherapy. For European health systems that have long recognized the benefits of proton therapy but faced significant infrastructure and financial barriers, this changes the question from whether to build a separate proton facility to how to integrate proton therapy into the radiotherapy programs they already operate.”

Advanced Capability in a Compact Footprint

The S250-FIT delivers Intensity Modulated Proton Therapy via Mevion’s HYPERSCAN® pencil beam scanning with the Adaptive Aperture® proton multi-leaf collimator and is designed to support DirectARC™ proton arc therapy. The system supports advanced image-guided and adaptive workflows and is FLASH research-ready.* The system is paired with Leo Cancer Care’s Marie® Upright Patient Positioning and CT Imaging System, the first commercial upright treatment platform with an integrated diagnostic CT, offering potential benefits in patient comfort and supporting organ motion management during treatment.

Built on Decades of U.S. and European Clinical Experience

The S250-FIT shares its core technology lineage with the MEVION S250i®, in clinical operation at Siteman Cancer Center at Washington University School of Medicine in the U.S. and at ZON-PTC at Maastro Clinic in the Netherlands, giving Mevion more than a decade of combined U.S. and European clinical experience with compact, single-room proton therapy. Mevion has now signed contracts with nine leading institutions globally for the S250-FIT, including Stanford Health Care, Loma Linda University Health, UNC Health, BayCare Health System, Atlantic Health System, and University of Nebraska Medical Center.

Meet Mevion at ESTRO 2026

Visit Mevion at Booth #C08:89 to engage with the Mevion team and discuss site planning, clinical workflows, and integration pathways with our clinical and engineering leadership.

*The FLASH Research Kit is not currently available for commercial sale or for human clinical use.

About Mevion Medical Systems

Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion’s compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i and MEVION S250-FIT™ with HYPERSCAN pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts, with a presence in Europe and Asia. For more information, please visit www.mevion.com.

MEVION S250-FIT™ proton therapy system showcased at ESTRO 2026, designed for integration in LINAC vaults.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260507172087/en/

Contact

Media Contact:
Jacqueline Abner-Pongratz
[email protected]

The MEVION S250-FIT™ Proton Therapy System
Company Logo

The MEVION S250-FIT™ Proton Therapy System

Company Logo

Read more

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Conference
  • Photo/Multimedia
  • Product/Service

Trending Articles

  • Starmer agrees investment deal with Japan as EU deal questioned

  • Elon Musk becomes world’s first trillionaire after SpaceX mega float

  • US and Iran agree to peace deal’s text, negotiators say

  • Thames Water, energy grid, rent prices: Burnham drums up public control agenda

  • Trump ban on AI access to foreign users forces Anthropic to suspend models

More from CityAM

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

    Business Wire
  • The Bath House banya: Contrast therapy in Belgravia

    Life&Style
    Historic bath house exterior with ornate architecture, showcasing vintage design elements and a serene garden setting.
  • Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

    Business Wire
  • Ascensia Diabetes Care Expands CONTOUR® Portfolio with CONTOUR®COMFORT Pen Needles to Bring Greater Stability and Control to the Everyday Injection Experience

    Business Wire
  • AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

    Business Wire
  • CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma

    Business Wire
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • News
  • Markets & Economics
  • Politics
  • Opinion
  • Life&Style
  • Personal Finance

Follow us for breaking news and latest updates

  • Facebook
  • X
  • Instagram
  • LinkedIn
Copyright 2026 CityAM Limited